Cartesian Therapeutics Inc. (RNAC)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XBER 
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On December 12, 2024, the Company issued to these employees options to purchase an aggregate of 25,602 shares of the Company's common stock with an exercise price of $20.12, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The option vests as to 25% on December 12, 2025, and then in three equal annual installments thereafter such that the options will be fully vested on December 12, 2028. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.
Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial
Phase 3 AURORA trial on track to commence in 1H2025; Primary endpoint to assess proportion of Descartes-08-treated participants with myasthenia gravis demonstrating an MG-ADL improvement of ≥3 points at Month 4 relative to placebo
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit
Company to host conference call and webcast with key opinion leader on December 3, 2024, at 7:30 a.m. ET Company to host conference call and webcast with key opinion leader on December 3, 2024, at 7:30 a.m. ET
Cartesian Therapeutics: Uncertainty Remains
Cartesian Therapeutics' stock has rebounded sharply recently despite no significant news, driven partly by insider buying after a disappointing Phase 2b trial for Descartes-08 in myasthenia gravis. The company leverages its RNA Armory platform for mRNA cell therapies, focusing on autoimmune diseases, with Descartes-08 and Descartes-15 as its main assets. Descartes-08 showed mixed results in Phase 2b for MG, raising concerns due to endpoint changes and trial anomalies, yet plans continue for a pivotal trial in 2025.
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to two new employees. On November 4, 2024, the Company issued to these employees options to purchase an aggregate of 4,854 shares of the Company's common stock with an exercise price of $19.11, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The option vests as to 25% on November 4, 2025, and then in three equal annual installments thereafter such that the options will be fully vested on November 4, 2028. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.
Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue Estimates
Cartesian Therapeutics, Inc. (RNAC) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $2.40 per share a year ago.
Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting
Company continues to expect to hold an End-of-Phase 2 meeting with the FDA by year-end Company continues to expect to hold an End-of-Phase 2 meeting with the FDA by year-end
Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last?
Cartesian Therapeutics, Inc. (RNAC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Cartesian Therapeutics Announces New Employment Inducement Grants
GAITHERSBURG, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to five new employees. On October 1, 2024, the Company issued to these employees options to purchase an aggregate of 60,961 shares of the Company's common stock with an exercise price of $17.11, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The option vests as to 25% on October 1, 2025, and then in three equal annual installments thereafter such that the options will be fully vested on October 1, 2028. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.
Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results
Cartesian Therapeutics, Inc.'s Descartes-08 mRNA CAR-T therapy shows promising Phase 2 results for myasthenia gravis without preconditioning chemotherapy. The company's RNA Armory platform enables precise, temporary cell modulation, reducing long-term side effects and avoiding genomic integration. Descartes-08 has received FDA Orphan and RMAT designations, with a Phase 3 trial expected to begin by the end of 2024.
Cartesian Therapeutics Announces New Employment Inducement Grant
GAITHERSBURG, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to a new employee. On September 3, 2024, the Company issued to this employee an option to purchase 3,864 shares of the Company's common stock with an exercise price of $13.12, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company's board of directors. The option vests as to 25% on September 3, 2025, and then in three equal annual installments thereafter such that the option will be fully vested on September 3, 2028. The option has a ten-year term. The option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee's entry into employment with the Company.
Cartesian Therapeutics, Inc. (RNAC) Q2 Earnings and Revenues Top Estimates
Cartesian Therapeutics, Inc. (RNAC) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of a loss of $0.81 per share. This compares to loss of $2.10 per share a year ago.
